Knopp Biosciences Announces Start of Phase 2 Clinical Trial Evaluating Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma
Knopp Biosciences LLC today announced the start of Phase 2 dose-ranging clinical trial in moderate-to-severe eosinophilic asthma. Recruitment in the trial is underway and the first patient has been enrolled. The Company anticipates reporting top-line data from this trial in the second half of 2020.
This 12-week biomarker study is planned to randomize approximately 100 patients with eosinophilic asthma to investigate the eosinophil response to three different doses of oral dexpramipexole. The primary outcome measure of this randomized, double-blind, placebo-controlled study is the change in blood absolute eosinophil count from Baseline to Week 12. The secondary outcome measures include changes in pre-bronchodilator FEV1 and asthma control outcomes (ACQ-7 questionnaire) from baseline to week 12.
“We estimate that there are more than two million moderate-to-severe eosinophilic asthma patients in the U.S. and are excited about further characterizing the clinical profile of oral dexpramipexole in this difficult-to-control disease,” said Michael E. Bozik, M.D., President and CEO of Knopp Biosciences.
Eosinophils are white-blood cells that play a central role in a number of debilitating diseases, including asthma, hypereosinophilic syndrome (HES), eosinophilic gastroenteritis, and atopic dermatitis. Knopp has previously reported the highly significant eosinophil-lowering effects of oral dexpramipexole including positive Phase 2 clinical trial results in HES .
ABOUT KNOPP BIOSCIENCES LLC
Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. In addition to developing oral dexpramipexole for eosinophil associated diseases, Knopp’s preclinical Kv7 platform is directed to small molecule treatments for KCNQ2 epileptic encephalopathy and other CNS hyperexcitability disorders. Please visit www.knoppbio.com
This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Acquires Two Office Buildings in Madrid19.9.2019 14:08:00 EEST | Press release
H.I.G. Capital, LLC ("H.I.G."), a leading global private equity investment firm with over $34 billion of equity capital under management, announced today that one of its affiliates has recently completed the acquisition of two office buildings totalling approximately 15,000 sqm in Madrid. One of the buildings has been recently refurbished to a high standard, while the other will undergo an extensive renovation, benefiting from the strong occupier market, which is attracting the interest of major international tenants. Terms were not disclosed. H.I.G. continues to add to its sizeable holdings of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small/midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Realty Partners Europe, commented: “Our focus in Spain is on high quality assets with the potential of becoming highly liquid institutional product as the result of
euNetworks Adds New High Density Fibre Networks in Milan and Madrid19.9.2019 13:21:00 EEST | Press release
euNetworks Group Limited (“euNetworks”), a Western European bandwidth infrastructure company, today announced that it has undertaken further network investment in Europe, building duct based, high fibre count networks in the cities of Milan and Madrid. Both new metro networks deliver a footprint covering key areas of bandwidth demand in the cities, such as financial districts and Silicon Alley in Madrid, as well as directly connecting the key data centres. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190919005351/en/ New high density fibre networks in Milan and Madrid (Photo: Business Wire) The company is focused on delivering high bandwidth data centre to data centre connectivity both between cities in Europe and within those cities. As a leading bandwidth infrastructure provider, euNetworks owns and operates deep fibre networks in 17 cities across Europe and also operates a highly differentiated long haul network that sp
Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factors19.9.2019 13:18:00 EEST | Press release
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a post-hoc analysis of the landmark EMPA-REG OUTCOME® trial that were presented at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain. Results suggest that the risk reduction in cardiovascular events, including cardiovascular death and hospitalisation for heart failure, seen with empagliflozin in the EMPA-REG OUTCOME® trial in adults with type 2 diabetes and established cardiovascular disease, were not affected by the number of controlled cardiovascular risk factors.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190919005347/en/ “Reducing cardiovascular risk in people with type 2 diabetes can be challenging, particularly in those with uncontrolled cardiovascular risk factors, such as blood sugar levels and blood pressure,” said Waheed Jamal, M.D., Corporate Vice President and Head of C
The LYCRA Company Announces New Solutions for the Circular Economy Under Its Planet Agenda Sustainability Platform19.9.2019 12:00:00 EEST | Press release
The LYCRA Company announced today that it is amplifying its Planet Agenda sustainability platform with the launch of LYCRA® EcoMade fiber, its first branded elastane made with pre-consumer content. The company also announced plans to convert the majority of COOLMAX® and THERMOLITE® fiber products to include recycled content by the end of 2021. The official launch will take place at Intertextile Shanghai, September 25-27. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190919005142/en/ The LYCRA Company Announces New Solutions for the Circular Economy Under Its Planet Agenda Sustainability Platform (Photo: Business Wire) “The Planet Agenda platform focuses on providing insights, technologies, products, and processes that can contribute to a more sustainable industry,” says Jean Hegedus, The LYCRA Company’s sustainability director. “Planet Agenda is built around three interdependent pillars: product sustainability, manufacturin
CONSUS Real Estate AG: Bondholders Invited to Vote on an Amendment of the Terms and Conditions of the EUR 200,000,000 4.00% Bonds Due 2022 (ISIN DE000A2G9H97)19.9.2019 11:35:00 EEST | Press release
As announced on 12 September 2019, Consus Real Estate AG (the Company) has now formally proposed to the bondholders of the EUR 200,000,000 4.00% bonds due 2022 (ISIN DE000A2G9H97) an amendment of the terms and conditions of the bonds (revised conversion mechanism to align with standard market conversion process), to be resolved upon by the bondholders in a voting without physical meeting. The request for voting is now published in the Federal Gazette (Bundesanzeiger) (www.bundesanzeiger.de). The voting period starts on Thursday, 10 October 2019, at 0:00 hrs and ends on Monday, 14 October 2019, at 24:00 hrs. All relevant documents are available on the Company's website www.consus.ag under "Investors / Creditors' Meeting". The issuer is solely responsible for the content of this announcement. Language English Company CONSUS Real Estate AG Kurfürstendamm 188-189 10707 Berlin Germany Phone +49 (0)30 965 357 90 300 E-mail email@example.com Internet www.consus.ag ISIN DE000A2DA414 WKN A2DA41 Li
Samsung Brings Revolutionary Software Innovation to PCIe Gen4 SSDs for Maximized Storage Performance19.9.2019 11:00:00 EEST | Press release
Samsung Electronics Co., Ltd., the world leader in advanced memory technology, today announced that it has brought the latest software innovations to the company's most cutting-edge PCIe Gen4 solid state drive (SSD) series, opening up a new paradigm in SSD performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190919005268/en/ Samsung Brings Revolutionary Software Innovation to PCIe Gen4 SSDs for Maximized Storage Performance (Graphic: Business Wire) "We are combining breakthrough speeds and capacities with revolutionary software solutions as we accelerate expansion in the premium SSD market," said Kye Hyun Kyung, executive vice president of Memory Solution Product & Development at Samsung Electronics. "We plan to introduce additional innovation led by our most advanced (sixth-generation) V-NAND in helping to trigger a lot more growth in the global IT market." 3 software innovations create new paradigm for ultra-high-ca
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom